Zoonoses

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Retrieved on: 
Monday, August 2, 2021
Health sciences, Medicine, Clinical medicine, Zoonoses, Infectious diseases, Nose, Dosage forms, Pandemics, Virus, COVID-19, Nasal spray

It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.

Key Points: 
  • It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.
  • Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
  • SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORS) to treat and prevent microbial infections in 2017.
  • Available at https://www.clinicaltrialsarena.com/news/sanotize-nasal-spray-reduces-co...
    2 SaNOtize's "revolutionary" Covid-19 nasal spray bolstered by Phase II trial data.

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, 3C-like protease, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Beta variant, SARS-CoV-2 Delta variant, Middle East respiratory syndrome–related coronavirus, COVID-20

BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

Key Points: 
  • BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.
  • Cocrystal previously announced that CDI-45205 and analogs exhibited broad-spectrum activity against the SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the Wuhan strain.
  • The broad-spectrum activity against these SARS-CoV-2 variants is highly encouraging as CDI-45205 previously demonstrated excellent in vivo efficacy in a MERS-CoV-2 infected animal model.
  • The Company continues to develop SARS-CoV-2 oral protease inhibitors and replication inhibitors using its proprietary drug discovery platform technology.

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Variants of SARS-CoV-2, COVID-19 pandemic in India, SARS-CoV-2 Delta variant, COVID-19, Variant, Delta, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

MENLO PARK, Calif. and AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (“mAb”) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.

Key Points: 
  • The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.
  • The Delta variant now accounts for 83% of new cases in the U.S., according to recent CDC data.
  • Demonstration that AUG-3387 effectively neutralizes the Delta variant in vitro is an encouraging step towards developing the therapy to slow and prevent ongoing spread of COVID-19.
  • Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially.

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Coronaviridae, Medicine, Health sciences, Zoonoses, COVID-19 vaccines, Sarbecovirus, Bat virome, Clinical trials, COVID-19 vaccine, Severe acute respiratory syndrome, Coronavirus, COVID-19

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

As Delta Variant Surges, Medicomp Systems Cancels Participation in HIMSS21

Retrieved on: 
Friday, July 30, 2021
Occupational safety and health, COVID-19, Public health, Zoonoses, SARS-CoV-2 Delta variant, Variants of SARS-CoV-2, Health, Articles

WASHINGTON, July 30, 2021 /PRNewswire/ -- Medicomp Systems, which makes medical data relevant, usable and actionable, today announced that it is canceling its participation in the HIMSS21 Global Health Conference & Exhibition, August 9-13, 2021, in Las Vegas.

Key Points: 
  • WASHINGTON, July 30, 2021 /PRNewswire/ -- Medicomp Systems, which makes medical data relevant, usable and actionable, today announced that it is canceling its participation in the HIMSS21 Global Health Conference & Exhibition, August 9-13, 2021, in Las Vegas.
  • With new COVID-19 cases surging due to the Delta variant, company leaders made the decision based on their commitment to keeping staff safe from infection.
  • Unfortunately, with the recent surge in COVID-19 cases due to the spread of the Delta variant, we have concluded that our attendance poses an unacceptable health risk for our staff and their families," said David Lareau, CEO of Medicomp Systems.
  • Medicomp Systems is a leading provider of solutions that make data usable for connected care and better outcomes.

Nomi Health Manages 30 Percent Spike in Demand for Free COVID-19 Testing in Utah

Retrieved on: 
Wednesday, July 28, 2021
Infectious diseases, General Health, Pharmaceutical, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Medical specialties, Articles, Medicine

Since June 28th, Nomi has managed a 30 percent rise in COVID-19 testing demands across the site, including Provo and Draper.

Key Points: 
  • Since June 28th, Nomi has managed a 30 percent rise in COVID-19 testing demands across the site, including Provo and Draper.
  • Nomi Health COVID-19 testing solutions are free and do not require any medical referral or presence of symptoms.
  • From the very beginning of the pandemic, Nomi has been a collaborative partner to the State of Utah providing quality, no-cost testing services to Utahns.
  • Our COVID-19 public health testing and vaccine programs are a perfect example of a more direct, digital-first health care model at work.

Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Immunology, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Cytokine, Medicine

Such dysregulated hyperactivation of these pathways is associated with the cytokine/chemokine storm observed in severe COVID-19 patients.

Key Points: 
  • Such dysregulated hyperactivation of these pathways is associated with the cytokine/chemokine storm observed in severe COVID-19 patients.
  • Ampio recently announced early positive data in its AP-014 Phase I clinical trial, utilizing Ampion in treating respiratory distress in patients as a result of COVID-19.
  • The study showed inhaled Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% over the Standard of Care (SOC) alone.
  • Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

ALABAMA SENATOR DIAL JOINS FOMO’S ADVISORY BOARD; OP-ED PUBLISHED ON BEATING COVID’S DELTA VARIANT

Retrieved on: 
Tuesday, July 27, 2021
Variants of SARS-CoV-2, Zoonoses, COVID-19, Occupational safety and health, Public health, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus 2, Health, Medical specialties

Chicago IL, July 27, 2021 (GLOBE NEWSWIRE) -- FOMO CORP. (OTC: FOMC) is pleased to announcethat Retired Senator Gerald Dial (R: Alabama 13th District) has joined FOMOs Advisory Board.

Key Points: 
  • Chicago IL, July 27, 2021 (GLOBE NEWSWIRE) -- FOMO CORP. (OTC: FOMC) is pleased to announcethat Retired Senator Gerald Dial (R: Alabama 13th District) has joined FOMOs Advisory Board.
  • According to Yale Medicine, the COVID-19 Delta variant is more contagious than other SARS-CoV-2 virus strains.
  • While research has shown that vaccinated people are typically protected from Delta, COVID-19 has demonstrated tenacity in its mutations.
  • Implementing these recommendations may increase our chances of beating the COVID-19 Delta variant and returning to some normalcy.

Vertosa Announces U.S. Patent, Engages Emery Pharma for Research That Applies Their Pharmaceutical Development Expertise to Cannabis-Infused Products

Retrieved on: 
Tuesday, July 27, 2021
Research, Tobacco, Specialty, Biotechnology, Alternative medicine, Health, Pharmaceutical, Retail, Science, Zoonoses, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Betacoronavirus, Vertosa, Emery Pharma, VERTOSA, EMERY PHARMA

Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.

Key Points: 
  • Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.
  • The team at Emery Pharma is skilled in Method Development and Validation, Characterization and Isolation of impurities, Stability Studies, and Release Testing.
  • Emery Pharma also develops methods and procedures in support of patent litigation , intellectual property, drug recalls, and product liability cases.
  • Since March 2020, Emery Pharma has engaged in development of a Sars-CoV-2 surrogate betacoronavirus assay for antiviral efficacy testing.

Therapeutic Solutions International Reports Preclinical Efficacy of JadiCell Umbilical Cord Mesenchymal Stem Cells in Animal Model Resembling COVID-19 Delta Variant Associated Lung Pathology

Retrieved on: 
Tuesday, July 27, 2021
Articles, Health, Zoonoses, Immune system, Virus, COVID-19

In contrast to other studies, the current experiments utilized significantly higher doses of the viral mimicking compounds in order to replicate infection with the delta variant.

Key Points: 
  • In contrast to other studies, the current experiments utilized significantly higher doses of the viral mimicking compounds in order to replicate infection with the delta variant.
  • It is published that the delta variant evades various immune mechanisms of the body, therefore causing a significantly higher viral load as compared to the original virus2.
  • In an FDA double blind, placebo controlled clinical trial the JadiCell was successful at substantially improving survival in end-stage patients with COVID-19 associated acute lung failure4.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.